Vera Therapeutics (NASDAQ:VERA – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($1.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.58) by $0.06, FiscalAI reports.
Vera Therapeutics Price Performance
NASDAQ VERA traded down $1.31 during trading on Monday, hitting $31.58. 1,036,132 shares of the stock traded hands, compared to its average volume of 1,432,085. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15. Vera Therapeutics has a 12-month low of $19.28 and a 12-month high of $56.05. The firm has a 50-day simple moving average of $36.58 and a 200-day simple moving average of $39.02. The company has a market capitalization of $2.27 billion, a P/E ratio of -5.70 and a beta of 0.92.
Wall Street Analysts Forecast Growth
Several equities research analysts recently issued reports on the stock. Guggenheim increased their target price on shares of Vera Therapeutics from $56.00 to $76.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. TD Cowen upped their price target on shares of Vera Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. HC Wainwright raised their price objective on shares of Vera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Bank of America lifted their target price on shares of Vera Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 target price on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Vera Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $84.58.
Insider Activity
In other news, CEO Marshall Fordyce sold 46,250 shares of the stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the transaction, the chief executive officer directly owned 151,994 shares in the company, valued at approximately $6,429,346.20. This represents a 23.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 83,250 shares of company stock worth $3,337,770. 15.90% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Vera Therapeutics
Several institutional investors have recently bought and sold shares of VERA. Los Angeles Capital Management LLC purchased a new position in shares of Vera Therapeutics in the 4th quarter worth $46,000. Quantbot Technologies LP bought a new position in shares of Vera Therapeutics in the 2nd quarter valued at about $51,000. Aster Capital Management DIFC Ltd bought a new position in shares of Vera Therapeutics in the 4th quarter valued at about $71,000. Tower Research Capital LLC TRC grew its position in Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after acquiring an additional 2,757 shares in the last quarter. Finally, Sandia Investment Management LP purchased a new position in Vera Therapeutics in the fourth quarter worth about $127,000. Institutional investors own 99.21% of the company’s stock.
About Vera Therapeutics
Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.
Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.
Read More
- Five stocks we like better than Vera Therapeutics
- SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
- 3 Dividend Champion Utilities for a Market That Can’t Sit Still
- These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI
- First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
